Senzime AB
Research Senzime AB (SEZI) on Bullrun: market cap SEK 557.33M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSEZI
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryMedical Devices
- CurrencySEK
- Market capSEK 557.33M
- Financial periodQ2 2026
- RevenueSEK 24.67M
- Net income-SEK 21.36M
- Free cash flow-SEK 17.90M
- Gross margin44.1%
Valuation Snapshot
latest market cap is SEK 557.33M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 104.02M | -SEK 137.42M | n/a | 33.4% | n/a | SEK 73.98M | SEK 14.01M | SEK 304.46M |
| FY2024 | SEK 58.48M | -SEK 118.73M | -SEK 108.30M | 34.4% | -0.97 | SEK 100.94M | SEK 22.67M | SEK 345.86M |
| FY2023 | SEK 35.75M | -SEK 134.15M | -SEK 114.86M | 23.3% | -1.45 | SEK 151.01M | n/a | SEK 375.48M |
| FY2022 | SEK 14.03M | -SEK 132.70M | -SEK 137.76M | -31.3% | -1.99 | SEK 26.04M | n/a | SEK 261.90M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-29 | SEK 557.33M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 SEK.
About Senzime AB
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, quantitative train of-four (TOF) monitoring refined by real-world patient data; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance sensor to measure the tissue's opposition to carrying an alternating electrical current.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Senzime AB's market cap?
Senzime AB's market capitalization is SEK 557.33M.
What does Senzime AB do?
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, quantitative train of-four (TOF) monitoring refined by real-world patient data; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance sensor to measure the tissue's opposition to carrying an alternating electrical current. It also provides additional products, including CliniSenz Analyzer and OnZurf Probe.